ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.150,71
-0,10%
S&P 500
5.303,27
0,12%
US Dollar vs BRL
5,1047
0,00%
Bitcoin
66.945,24
-0,20%
Brent Oil
83,76
0,00%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Ocular Therapeutix Inc (OCUL)

  7. Ocular Therapeutix Inc (OCUL) Notícias

OCUL

Ocular Therapeutix (OCUL)

Ocular Therapeutix Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:OCUL
DataHoraFonteTítuloCódigoCompanhia
07/05/202417:22Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:OCULOcular Therapeutix Inc
07/05/202417:20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OCULOcular Therapeutix Inc
07/05/202417:05GlobeNewswire Inc.Ocular Therapeutix™ Reports First Quarter 2024 ResultsNASDAQ:OCULOcular Therapeutix Inc
07/05/202417:01Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:OCULOcular Therapeutix Inc
06/05/202421:16GlobeNewswire Inc.Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:OCULOcular Therapeutix Inc
06/05/202408:30GlobeNewswire Inc.Ocular Therapeutix™ to Present at Two Upcoming Investor ConferencesNASDAQ:OCULOcular Therapeutix Inc
03/05/202408:30GlobeNewswire Inc.Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024NASDAQ:OCULOcular Therapeutix Inc
01/05/202408:30GlobeNewswire Inc.Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024NASDAQ:OCULOcular Therapeutix Inc
11/03/202417:12Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:OCULOcular Therapeutix Inc
11/03/202417:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCULOcular Therapeutix Inc
11/03/202407:39IH Market NewsU.S. Index Futures Dip Ahead of Inflation Data and Oracle’s Earnings; Oil Prices Edge HigherNASDAQ:OCULOcular Therapeutix Inc
27/02/202418:43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OCULOcular Therapeutix Inc
26/02/202422:04Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:OCULOcular Therapeutix Inc
19/02/202411:00PR Newswire (US)AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic ConjunctivitiNASDAQ:OCULOcular Therapeutix Inc
15/02/202410:00GlobeNewswire Inc.Ocular Therapeutix™ Appoints Steve Meyers to Chief Commercial OfficerNASDAQ:OCULOcular Therapeutix Inc
14/02/202421:48Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:OCULOcular Therapeutix Inc
13/02/202409:37GlobeNewswire Inc.Ocular Therapeutix™ Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI™ in Wet AMDNASDAQ:OCULOcular Therapeutix Inc
05/02/202418:41Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:OCULOcular Therapeutix Inc
28/12/202318:17Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:OCULOcular Therapeutix Inc
18/12/202318:52Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:OCULOcular Therapeutix Inc
18/12/202318:01GlobeNewswire Inc.Ocular Therapeutix™ Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional SharesNASDAQ:OCULOcular Therapeutix Inc
14/12/202318:09Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:OCULOcular Therapeutix Inc
14/12/202300:09GlobeNewswire Inc.Ocular Therapeutix™ Announces Pricing of Public Offering of Common StockNASDAQ:OCULOcular Therapeutix Inc
13/12/202321:07Dow Jones NewsStocks to Watch: Adobe, Amtech Systems, Ocular TherapeutixNASDAQ:OCULOcular Therapeutix Inc
13/12/202318:01GlobeNewswire Inc.Ocular Therapeutix™ Announces Proposed Public Offering of Common StockNASDAQ:OCULOcular Therapeutix Inc
17/11/202302:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:OCULOcular Therapeutix Inc
08/11/202310:00GlobeNewswire Inc.Ocular Therapeutix™ to Present at Three Upcoming Investor ConferencesNASDAQ:OCULOcular Therapeutix Inc
07/11/202319:06Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:OCULOcular Therapeutix Inc
07/11/202318:01GlobeNewswire Inc.Ocular Therapeutix™ Provides Third Quarter 2023 Financial Results and Corporate UpdateNASDAQ:OCULOcular Therapeutix Inc
01/11/202309:00GlobeNewswire Inc.Ocular Therapeutix™ Receives FDA Agreement Under Special Protocol Assessment (SPA) for its First Pivotal Clinical Trial of OTX-TKI in Wet AMDNASDAQ:OCULOcular Therapeutix Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:OCUL

Seu Histórico Recente

BSTP
ZRXEUR
0x protocol
ASX
AEKN
LSE
0A8E
Xeris Biopharma
NASDAQ
CTEC
Global X CleanTech ETF
GATE
TIDALUSDT
Tidal Token
TSX
DRPOS
Desjardin
ASX
PXXNA
PolarX
TSXV
SLV
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados